SOX5 inhibition overcomes PARP inhibitor resistance in BRCA-mutated breast and ovarian cancer.
- Published in:
- Cell Death & Disease, 2025, v. 16, n. 1, p. 1, doi. 10.1038/s41419-025-07660-7
- By:
- Publication type:
- Article
Works matching AU Hong, Sa Deok
Results: 6
1
2
Combined PI3K Inhibitor and Eribulin Enhances Anti-Tumor Activity in Preclinical Models of Paclitaxel-Resistant, PIK3CA-Mutated Endometrial Cancer.
- Published in:
- Cancers, 2023, v. 15, n. 19, p. 4887, doi. 10.3390/cancers15194887
- By:
- Publication type:
- Article
3
Trastuzumab-Mediated Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) Enhances Natural Killer Cell Cytotoxicity in HER2-Overexpressing Ovarian Cancer.
- Published in:
- International Journal of Molecular Sciences, 2024, v. 25, n. 21, p. 11733, doi. 10.3390/ijms252111733
- By:
- Publication type:
- Article
4
PSPC1 Inhibition Synergizes with Poly(ADP-ribose) Polymerase Inhibitors in a Preclinical Model of BRCA-Mutated Breast/Ovarian Cancer.
- Published in:
- International Journal of Molecular Sciences, 2023, v. 24, n. 23, p. 17086, doi. 10.3390/ijms242317086
- By:
- Publication type:
- Article
5
Synergism of AZD6738, an ATR Inhibitor, in Combination with Belotecan, a Camptothecin Analogue, in Chemotherapy-Resistant Ovarian Cancer.
- Published in:
- International Journal of Molecular Sciences, 2021, v. 22, n. 3, p. 1223, doi. 10.3390/ijms22031223
- By:
- Publication type:
- Article
6
Targeting PEG10 as a novel therapeutic approach to overcome CDK4/6 inhibitor resistance in breast cancer.
- Published in:
- Journal of Experimental & Clinical Cancer Research (17569966), 2023, v. 42, n. 1, p. 1, doi. 10.1186/s13046-023-02903-x
- By:
- Publication type:
- Article